Single-cell techniques have convincingly demonstrated that tumor tissue usually contains multiple genetically defined cell subclones with different gene mutation sets as well as various transcriptional profiles, but the spatial heterogeneity of the microenvironment and the macrobiological characteristics of the tumor ecosystem have not been described. For the past few years, spatial multi-omics technologies have revealed the cellular interactions, microenvironment, and even systemic tumor-host interactions in the tumor ecosystem at the spatial level, which can not only improve classical therapies such as surgery, radiotherapy, and chemotherapy but also promote the development of emerging targeted therapies in immunotherapy. Here, we review some emerging spatial omics techniques in cancer research and therapeutic applications and propose prospects for their future development.
XiaLOyangLLinJ, et al. The cancer metabolic reprogramming and immune response. Mol Cancer2021; 20: 28.
2.
ChenXSongE.The theory of tumor ecosystem. Cancer Commun (Lond)2022; 42: 587-608.
3.
SunYWuPZhangZ, et al. Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell2024; 42: 135-156.e117.
4.
GouinKH3rdIngNPlummerJT, et al. An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. Nat Commun2021; 12: 4906.
5.
RaviVMWillPKueckelhausJ, et al. Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. Cancer Cell2022; 40: 639-655.e613.
6.
TavernariDBattistelloEDheillyE, et al. Nongenetic evolution drives lung adenocarcinoma spatial heterogeneity and progression. Cancer Discov2021; 11: 1490-1507.
7.
GerlingerMRowanAJHorswellS, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med2012; 366: 883-892.
8.
ZhaoTChiangZDMorrissJW, et al. Spatial genomics enables multi-modal study of clonal heterogeneity in tissues. Nature2022; 601: 85-91.
9.
LomakinASvedlundJStrellC, et al. Spatial genomics maps the structure, nature and evolution of cancer clones. Nature2022; 611: 594-602.
10.
DhainautMRoseSAAkturkG, et al. Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell2022; 185: 1223-1239.e1220.
11.
StåhlPLSalménFVickovicS, et al. Visualization and analysis of gene expression in tissue sections by spatial transcriptomics. Science2016; 353: 78-82.
12.
BerglundEMaaskolaJSchultzN, et al. Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nat Commun2018; 9: 2419.
13.
ThraneKErikssonHMaaskolaJ, et al. Spatially resolved transcriptomics enables dissection of genetic heterogeneity in stage III cutaneous malignant melanoma. Cancer Res2018; 78: 5970-5979.
14.
SchürchCMBhateSSBarlowGL, et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell2020; 183: 838.
15.
WangYMashockMTongZ, et al. Changing technologies of RNA sequencing and their applications in clinical oncology. Front Oncol2020; 10: 447.
16.
TrcekTLionnetTShroffH, et al. MRNA quantification using single-molecule FISH in Drosophila embryos. Nat Protoc2017; 12: 1326-1348.
17.
ShafferSMDunaginMCTorborgSR, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature2017; 546: 431-435.
18.
ChenKHBoettigerANMoffittJR, et al. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science2015; 348: aaa6090.
19.
LubeckECoskunAFZhiyentayevT, et al. Single-cell in situ RNA profiling by sequential hybridization. Nat Methods2014; 11: 360-361.
20.
EngCLLawsonMZhuQ, et al. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature2019; 568: 235-239.
21.
LewisSMAsselin-LabatMLNguyenQ, et al. Spatial omics and multiplexed imaging to explore cancer biology. Nat Methods2021; 18: 997-1012.
22.
LeeJHDaugharthyERScheimanJ, et al. Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues. Nat Protoc2015; 10:442-458.
23.
WangXAllenWEWrightMA, et al. Three-dimensional intact-tissue sequencing of single-cell transcriptional states. Science2018; 361 (6400):eaat5691.
24.
WuSZAl-EryaniGRodenDL, et al. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet2021; 53: 1334-1347.
25.
JiALRubinAJThraneK, et al. Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma. Cell2020; 182: 497-514.e422.
26.
MoncadaRBarkleyDWagnerF, et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat Biotechnol2020; 38: 333-342.
27.
ZhaoNZhangYChengR, et al. Spatial maps of hepatocellular carcinoma transcriptomes highlight an unexplored landscape of heterogeneity and a novel gene signature for survival. Cancer Cell Int2022; 22: 57.
28.
MortonMLBaiXMerryCR, et al. Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens. Lung Cancer2014; 85: 31-39.
29.
HeJMaurerHCHolmstromSR, et al. Transcriptional deconvolution reveals consistent functional subtypes of pancreatic cancer epithelium and stroma. bioRxiv2018; 10.1101/288779
30.
LamKHBLeonAJHuiW, et al. Topographic mapping of the glioblastoma proteome reveals a triple-axis model of intra-tumoral heterogeneity. Nat Commun2022; 13: 116.
31.
DanaherPKimYNelsonB, et al. Advances in mixed cell deconvolution enable quantification of cell types in spatial transcriptomic data. Nat Commun2022; 13: 385.
32.
BradyLKrinerMColemanI, et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun2021; 12: 1426.
33.
OmilianARShengHHongCC, et al. Multiplexed digital spatial profiling of invasive breast tumors from Black and White women. Mol Oncol2022; 16: 54-68.
34.
RicoKDuanSPandeyRL, et al. Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours. BMJ Open Gastroenterol2021; 8: e000765.
35.
WangNWangRLiX, et al. Tumor microenvironment profiles reveal distinct therapy-oriented proteogenomic characteristics in colorectal cancer. Front Bioeng Biotechnol2021; 9: 757378.
36.
KumarVRamnarayananKSundarR, et al. Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov2022; 12: 670-691.
37.
Jerby-ArnonLNeftelCShoreME, et al. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nat Med2021; 27: 289-300.
38.
ZhangQAbdoRIosefC, et al. The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis. Nat Commun2022; 13: 5983.
39.
BlackSPhillipsDHickeyJW, et al. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat Protoc2021; 16: 3802-3835.
40.
SchürchCMBhateSSBarlowGL, et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell2020; 182: 1341-1359.e1319.
41.
De Vargas RoditiLJacobsARueschoffJH, et al. Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer. Cell Rep Med2022; 3: 100604.
42.
GonzalezHMeiWRoblesI, et al. Cellular architecture of human brain metastases. Cell2022; 185: 729-745.e720.
43.
XinZLinMHaoZ, et al. The immune landscape of human thymic epithelial tumors. Nat Commun2022; 13: 5463.
44.
WangZHeLLiW, et al. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. J Immunother Cancer2021; 9: e002787.
45.
JacksonHWFischerJRZanotelliVRT, et al. The single-cell pathology landscape of breast cancer. Nature2020; 578: 615-620.
46.
ShengJZhangJWangL, et al. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. Gut2022; 71: 1176-1191.
47.
SorinMRezanejadMKarimiE, et al. Single-cell spatial landscapes of the lung tumour immune microenvironment. Nature2023; 614: 548-554.
48.
WagnerJRapsomanikiMAChevrierS, et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell2019; 177: 1330-1345.e1318.
49.
KerenLBosseMMarquezD, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell2018; 174: 1373-1387.e1319.
50.
IrmischABonillaXChevrierS, et al. The Tumor Profiler Study: Integrated, multi-omic, functional tumor profiling for clinical decision support. Cancer Cell2021; 39: 288-293.
51.
MundACosciaFKristonA, et al. Deep visual proteomics defines single-cell identity and heterogeneity. Nat Biotechnol2022; 40: 1231-1240.
52.
SeeleyEHCaprioliRM.3D imaging by mass spectrometry: a new frontier. Anal Chem2012; 84: 2105-2110.
53.
SantoroALDrummondRDSilvaIT, et al. In situ DESI-MSI lipidomic profiles of breast cancer molecular subtypes and precursor lesions. Cancer Res2020; 80: 1246-1257.
54.
RandallECZadraGChettaP, et al. Molecular characterization of prostate cancer with associated Gleason Score using mass spectrometry imaging. Mol Cancer Res2019; 17: 1155-1165.
55.
TuASaidNMuddimanDC.Spatially resolved metabolomic characterization of muscle invasive bladder cancer by mass spectrometry imaging. Metabolomics2021; 17: 70.
56.
VosDRNEllisSRBalluffB, et al. Experimental and data analysis considerations for three-dimensional mass spectrometry imaging in biomedical research. Mol Imaging Biol2021; 23: 149-159.
57.
YoungRSEClaesBSRBowmanAP, et al. Isomer-resolved imaging of prostate cancer tissues reveals specific lipid unsaturation profiles associated with lymphocytes and abnormal prostate epithelia. Front Endocrinol (Lausanne)2021; 12: 689600.
58.
GouwAMMargulisKLiuNS, et al. The MYC oncogene cooperates with sterol-regulated element-binding protein to regulate lipogenesis essential for neoplastic growth. Cell Metab2019; 30: 556-572.e555.
59.
ChenFDaiXZhouCC, et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut2022; 71: 1315-1325.
60.
NardyAFFreire-de-LimaLFreire-de-LimaCG, et al. The sweet side of immune evasion: role of glycans in the mechanisms of cancer progression. Front Oncol2016; 6: 54.
61.
ScottEMunkleyJ.Glycans as biomarkers in prostate cancer. Int J Mol Sci2019; 20: 1389.
62.
FreitasDCamposDGomesJ, et al. O-glycans truncation modulates gastric cancer cell signaling and transcription leading to a more aggressive phenotype. EBioMedicine2019; 40: 349-362.
63.
DohertyMTheodoratouEWalshI, et al. Plasma N-glycans in colorectal cancer risk. Sci Rep2018; 8: 8655.
64.
JianYXuZXuC, et al. The roles of glycans in bladder cancer. Front Oncol2020; 10: 957.
65.
YangXSongXZhangX, et al. In situ DESI-MSI lipidomic profiles of mucosal margin of oral squamous cell carcinoma. EBioMedicine2021; 70: 103529.
66.
ChoY-TSuHChiangY-Y, et al. Fine needle aspiration combined with matrix-assisted laser desorption ionization time-of-flight/mass spectrometry to characterize lipid biomarkers for diagnosing accuracy of breast cancer. Clin Breast Cancer2017; 17: 373−381.
67.
WangJKunzkeTPradeVM, et al. Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients. Clin Cancer Res2022; 28: 2865-2877.
68.
ZhiYWangQZiM, et al. Spatial transcriptomic and metabolomic landscapes of oral submucous fibrosis-derived oral squamous cell carcinoma and its tumor microenvironment. Adv Sci (Weinh)2024; 11: e2306515.
69.
MengYHangWZareRN: Microlensed fiber allows subcellular imaging by laser-based mass spectrometry. Nat Protoc2023; 18: 2558-2578.
70.
EberlinLSMargulisKPlanell-MendezI, et al. Pancreatic cancer surgical resection margins: molecular assessment by mass spectrometry imaging. PLoS Med2016; 13: e1002108.
71.
PirroVAlfaroCMJarmuschAK, et al. Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry. Proc Nat Acad Sci USA2017; 114: 6700−6705.
72.
NishidateMHayashiMAikawaH, et al. Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development. Drug Metab Pharmacokinet2019; 34: 209-216.
73.
FuchsKKissABizePE, et al. Mapping of drug distribution in the rabbit liver tumor model by complementary fluorescence and mass spectrometry imaging. J Control Release2018; 269: 128-135.
74.
GrosecloseMRLaffanSBFrazierKS, et al. Imaging MS in toxicology: An investigation of juvenile rat nephrotoxicity associated with dabrafenib administration. J Am Soc Mass Spectrom2015; 26: 887-898.
75.
TognettiMGaborAYangM, et al. Deciphering the signaling network of breast cancer improves drug sensitivity prediction. Cell Syst2021; 12: 401 -418.e412.
76.
Cui ZhouDJayasingheRGChenS, et al. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Nat Genet2022; 54: 1390-1405.
77.
MariathasanSTurleySJNicklesD, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature2018; 554: 544-548.
78.
LiuXBaoXHuM, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature2020; 588: 693-698.
79.
ImtiyazHZWilliamsEPHickeyMM, et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest2010; 120: 2699-2714.
80.
ChenJLuoHLiuY, et al. Oxygen-self-produced nanoplatform for relieving hypoxia and breaking resistance to sonodynamic treatment of pancreatic cancer. ACS Nano2017; 11: 12849-12862.
81.
FukumuraDKloepperJAmoozgarZ, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol2018; 15: 325-340.
82.
Sautès-FridmanCPetitprezFCalderaroJ, et al. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer2019; 19: 307-325.
83.
CabritaRLaussMSannaA, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature2020; 577: 561-565.
84.
HelminkBAReddySMGaoJ, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature2020; 577: 549-555.
85.
Alonso-NoceloMRaimondoTMViningKH, et al. Matrix stiffness and tumor-associated macrophages modulate epithelial to mesenchymal transition of human adenocarcinoma cells. Biofabrication2018; 10: 035004.
86.
NajafiMFarhoodBMortezaeeK.Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem2019; 120: 2782-2790.
87.
BianYLiWKremerDM, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature2020; 585: 277-282.
88.
ZhongWWeissHLJayswalRD, et al. Extracellular redox state shift: A novel approach to target prostate cancer invasion. Free Radic Biol Med2018; 117: 99-109.
89.
LuSSteinJERimmDL, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: A systematic review and meta-analysis. JAMA Oncol2019; 5: 1195-1204.
90.
VathiotisIAYangZReevesJ, et al. Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality. NPJ Precis Oncol2021; 5: 45.
91.
QuarantaMScaramellaFCostanzoG.Biocompatibility of new porcelains in dentistry. Dent Cadmos1987; 55:49-53.
92.
Freed-PastorWALambertLJElyZA, et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell2021; 39: 1342-1360.e1314.
93.
Sandström GerdtssonAKnulstMBotlingJ, et al. Phenotypic characterization of spatial immune infiltration niches in non-small cell lung cancer. Oncoimmunology2023; 12: 2206725.
94.
YangJChenYJingY, et al. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat Rev Clin Oncol2023; 20: 211-228.
95.
BosseKRRamanPZhuZ, et al. Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma. Cancer Cell2017; 32: 295-309.e212.
96.
HouAJChenLCChenYY.Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discov2021; 20: 531-550.
97.
NayakVPatraSSinghKR, et al. Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeutics. Environ Res2023; 235: 116573.
98.
SchäferDTomiukSKüsterLN, et al. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun2021; 12: 1453.
99.
SeferbekovaZLomakinAYatesLR, et al. Spatial biology of cancer evolution. Nat Rev Genet2023; 24: 295-313.
